HUTCHMED and AstraZeneca Submit US NDA for ORPATHYS Plus TAGRISSO
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
MET Overexpression
Advertisement
Kazia Paxalisib Shows Potential in Resistant Colorectal Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics Limited has reported new preclinical and translational findings suggesting that its investigational...
HUTCHMED Reports Phase III Lung Cancer Trial Success
Hong Kong, Shanghai, China, and Florham Park, New Jersey, August 31, 2026 HUTCHMED (China) Limited has announced positive high-level...
HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
Advertisement
